MPH's business activities consist of investing in companies with the aim of capital appreciation, with strategic focus on acquisition and development of companies particularly in growth segments of the healthcare market and pharmaceutical industry. The portfolio comprises HAEMATO AG (pharmaceutical generics), M1 Kliniken AG (aesthetic medicine), and MPH Ventures (venture capital in cytostatic solutions and real estate).
Cyborg Score Rationale
Equity decreased 26% from EUR 277.9M (Dec 2024) to EUR 205.1M (June 2025), with net asset value per share falling from EUR 64.90 to EUR 47.91. Mixed portfolio performance reflects healthcare sector challenges, though underlying assets show operational strength.
Top Insights
Portfolio-driven business model with exposure to high-growth sectors (aesthetic medicine, specialty pharmaceuticals, oncology generics)
Recent equity decline of 26% in H1 2025 signals valuation compression or challenging trading environment
Analyst consensus target of EUR 43.90 represents 146%+ upside from current levels, suggesting significant value recognition potential
Minimal employee base (2 FTE) indicates pure holding company structure with operational leverage through portfolio companies